ALK-Abelló A/S ALK-Abelló A/S

ALK-Abelló A/S

ALK-B

Rank in Stocks #2433
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Share Price
$36.23
Last synced: 2026-10-16
Market Cap
$8.04B
Change (1 day)
-1.72%
Change (1 year)
12.00%
Country
DK
Trade ALK-Abelló A/S (ALK-B)

Category

Healthcare
EPS for ALK-Abelló A/S (ALK-B)
EPS as of 2026 TTM: 0
According to ALK-Abelló A/S latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for ALK-Abelló A/S from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$-7.98 -
US
$-5.29 -
AU
- -
CH
$27.74 -
NL